mitoxantrone has been researched along with Local Neoplasm Recurrence in 148 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We treated elderly patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) using a CMD (CPT-11, mitoxantrone [MIT], dexamethasone [DEX]) regimen and studied its safety and efficacy." | 9.12 | Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. ( Bessho, M; Higashihara, M; Kohori, M; Niitsu, N, 2007) |
| " In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%." | 9.12 | Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. ( Briel, J; Colevas, AD; Gore, SD; Greer, J; Hattenburg, C; Jones, RJ; Karp, JE; Levis, MJ; Smith, BD; Wright, JJ, 2007) |
| "To investigate the safety and feasibility of a novel form of treatment offered by the direct intraoperative application of a Surgifoam-mitoxantrone mix into a glioblastoma multiforme postresection cavity." | 9.12 | Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. ( Boiardi, A; Broggi, G; Broggi, M; Ferroli, P; Franzini, A; Lamperti, M; Maccagnano, E, 2006) |
| "The two doses of mitoxantrone resulted in similar efficacy for the prevention of superficial bladder cancer recurrences, with the dose of 10 mg of mitoxantrone being related to fewer side effects." | 9.11 | Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. ( Deliveliotis, C; Dimopoulos, C; Giannopoulos, A; Papatsoris, AG, 2004) |
| "This randomized trial was conducted to compare the efficacy and side effects of intravesical mitoxantrone instillation with those of doxorubicin in superficial bladder cancer following transurethral resection." | 9.10 | A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer. ( Chen, WH; Huang, JS; Lai, CH; Lan, YJ; Liaw, CC; Lin, CC; Liu, JP; Wang, CH, 2003) |
| "Fourteen patients with recurrent breast cancer were treated with a combination of mitoxantrone (10 mg/m2 iv, day 1), vincristine (1 mg/m2 iv, day 1) and prednisolone (30 mg/day day 1-7)." | 9.08 | [Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer]. ( Fukunaga, M; Iba, T; Kidokoro, A; Momose, F; Yagi, Y, 1995) |
| "Randomized clinical trials were conducted in patients with advanced/relapsed breast cancer, using CMitF (mitoxantrone, cyclophosphamide, and 5-fluorouracil) regimen in comparison with CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen." | 9.06 | [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer]. ( Sakai, K; Taguchi, T; Terasawa, T; Wada, H, 1986) |
| "Combination treatment with mitoxantrone hydrochloride, vincristine sulfate and prednisolone is an effective treatment for breast cancer." | 7.72 | Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer. ( Aoki, T; Katsumata, K; Koyanagi, Y; Kusama, M; Tomioka, H, 2003) |
| "The authors examined the survival rates of 60 patients with breast cancer who underwent parasternal lymph node biopsy during surgery with axillary lymph node dissection and had histologically confirmed axillary node metastasis followed by adjuvant doxorubicin- or mitoxantrone-containing combination chemotherapy to ascertain whether administration of anthracycline or its analogue improved the prognosis of both axillary and parasternal node-positive patients." | 7.70 | Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy. ( Kanno, M; Nakamura, S; Noguchi, M; Terasaki, Y; Tsugawa, K; Uotani, C; Yamanaka, S, 2000) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 7.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| " Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present." | 7.69 | Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. ( Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994) |
| "We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i." | 7.69 | [Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997) |
| "We undertook a phase I-II trail of loco-regional mitoxantrone in 12 patients affected by malignant gliomas." | 7.69 | Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. ( Boiardi, A; Broggi, G; Pozzi, A; Salmaggi, A; Silvani, A, 1996) |
| "To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)." | 7.68 | A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990) |
| "Intensive sequential chemotherapy with mitoxantrone, 12 mg/m2/d on days 1 through 3, etoposide, 200 mg/m2/d as a continuous infusion on days 8 through 10, and cytarabine, 500 mg/m2/d as a continuous infusion on days 1 through 3 and 8 through 10 was administered to 72 patients aged less than 60 years with previously treated acute myelogenous leukemia (AML)." | 7.68 | Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. ( Archimbaud, E; Cordonnier, C; Devaux, Y; Dreyfus, F; Fenaux, P; Fiere, D; Jaubert, J; Leblond, V; Michallet, M; Travade, P, 1991) |
| "The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed." | 7.67 | [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984) |
| "The effects of combination chemotherapy including mitoxantrone (MXN) "M-VEMFH" for advanced breast cancer were studied." | 7.67 | [Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer]. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sugiura, I, 1985) |
| "Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydrochloride)." | 7.66 | Mitoxantrone in patients with acute leukemia in relapse. ( Cuttner, J; Holland, JF; Ohnuma, T; Paciucci, PA; Silver, RT, 1983) |
| "In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life." | 6.70 | 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001) |
| "Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance." | 6.67 | Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994) |
| "Multiple myeloma has low complete remission rate and high recurrence rate." | 5.33 | [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]. ( Hong, WD; Li, J; Luo, SK; Tong, XZ; Zhao, Y, 2005) |
| "Concomitant radiotherapy with adjuvant fluorouracil, mitoxantrone, and cyclophosphamide has significantly better locoregional control in node-positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity." | 5.12 | A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. ( Bertheault-Cvitkovic, F; Castèra, D; Combe, M; de la Lande, B; Demange, L; Garbay, JR; Graïc, Y; Krzisch, C; Leduc, B; Lucas, V; Mouret-Fourme, E; Nguyen, TD; Noguès, C; Rouëssé, J; Serin, D; Villet, R, 2006) |
| "To investigate the safety and feasibility of a novel form of treatment offered by the direct intraoperative application of a Surgifoam-mitoxantrone mix into a glioblastoma multiforme postresection cavity." | 5.12 | Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. ( Boiardi, A; Broggi, G; Broggi, M; Ferroli, P; Franzini, A; Lamperti, M; Maccagnano, E, 2006) |
| "We treated elderly patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) using a CMD (CPT-11, mitoxantrone [MIT], dexamethasone [DEX]) regimen and studied its safety and efficacy." | 5.12 | Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. ( Bessho, M; Higashihara, M; Kohori, M; Niitsu, N, 2007) |
| "Of our study was to assess and compare the outcome of patients undergoing anthracycline based neoadjuvant chemotherapy in locally advanced primary breast cancers with patients receiving mitoxantrone, methotrexate and mitomycin (MMM) as neoadjuvant agents." | 5.12 | Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience. ( Agrawal, A; Asgeirsson, KS; Chan, SY; Cheung, KL; Ellis, IO; Mathew, J; Mukherjee, A; Robertson, JF, 2007) |
| " In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%." | 5.12 | Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. ( Briel, J; Colevas, AD; Gore, SD; Greer, J; Hattenburg, C; Jones, RJ; Karp, JE; Levis, MJ; Smith, BD; Wright, JJ, 2007) |
| "The two doses of mitoxantrone resulted in similar efficacy for the prevention of superficial bladder cancer recurrences, with the dose of 10 mg of mitoxantrone being related to fewer side effects." | 5.11 | Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. ( Deliveliotis, C; Dimopoulos, C; Giannopoulos, A; Papatsoris, AG, 2004) |
| "Twenty-three patients with multifocal superficial bladder cancer (stage Ta - T1) unresponsive to at least 3 different intravesical agents, were enrolled in a phase II study in order to evaluate the prophylactic effects of intravesical Mitoxantrone (20 mg) after complete endoscopic resection (TUR) of any papillary tumor." | 5.10 | [Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study]. ( Abatangelo, G; Bassi, PF; Carando, R; Dal Moro, F; Piazza, N; Spinadin, R; Tavolini, IM, 2003) |
| "This randomized trial was conducted to compare the efficacy and side effects of intravesical mitoxantrone instillation with those of doxorubicin in superficial bladder cancer following transurethral resection." | 5.10 | A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer. ( Chen, WH; Huang, JS; Lai, CH; Lan, YJ; Liaw, CC; Lin, CC; Liu, JP; Wang, CH, 2003) |
| "Thirty cases (breast cancer-20 cases, malignant lymphoma-4 cases, different malignancies-6 cases) of histologically/cytologically verified malignant pleural effusion (MPE) in 29 patients were treated with intrapleurally instilled mitoxantrone (30 mg)." | 5.08 | Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study. ( Aasebø, U; Norum, J; Sager, G; Slørdal, L, 1997) |
| "Fourteen patients with recurrent breast cancer were treated with a combination of mitoxantrone (10 mg/m2 iv, day 1), vincristine (1 mg/m2 iv, day 1) and prednisolone (30 mg/day day 1-7)." | 5.08 | [Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer]. ( Fukunaga, M; Iba, T; Kidokoro, A; Momose, F; Yagi, Y, 1995) |
| "In a non-randomized clinical trial, combined intraperitoneal therapy with recombinant interferon alpha-2b (20-50 MU) and mitoxantrone (20-50 mg) was studied for recurrent ovarian cancer with ascites." | 5.07 | Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer. ( Gröhn, P; Kivinen, S; Mäenpää, J; Räisänen, I; Sipilä, P; Väyrynen, M, 1994) |
| "Twenty-nine evaluable patients with metastatic or recurrent leiomyosarcoma or malignant mixed mesodermal tumors of the uterus were treated with mitoxantrone 12 mg/m2 every 3 weeks." | 5.06 | Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. ( Adcock, L; Beecham, J; Bundy, BN; Muss, HB, 1990) |
| "Randomized clinical trials were conducted in patients with advanced/relapsed breast cancer, using CMitF (mitoxantrone, cyclophosphamide, and 5-fluorouracil) regimen in comparison with CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen." | 5.06 | [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer]. ( Sakai, K; Taguchi, T; Terasawa, T; Wada, H, 1986) |
| "The efficacy of fludarabine in combination with an intermediate dose of cytosine arabinoside, mitoxantrone, and G-CSF (FLANG; fludarabine 30 mg/m(2)/day, cytosine arabinoside 1 g/m(2)/day, mitoxantrone 10 mg/m(2)/day, and G-CSF 300 μg/day for 5 days) was evaluated in patients with refractory or relapsed acute myelogenous leukemia (AML)." | 3.77 | FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. ( Cho, BS; Cho, SG; Choi, SM; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS, 2011) |
| "Combination treatment with mitoxantrone hydrochloride, vincristine sulfate and prednisolone is an effective treatment for breast cancer." | 3.72 | Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer. ( Aoki, T; Katsumata, K; Koyanagi, Y; Kusama, M; Tomioka, H, 2003) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 3.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "The authors examined the survival rates of 60 patients with breast cancer who underwent parasternal lymph node biopsy during surgery with axillary lymph node dissection and had histologically confirmed axillary node metastasis followed by adjuvant doxorubicin- or mitoxantrone-containing combination chemotherapy to ascertain whether administration of anthracycline or its analogue improved the prognosis of both axillary and parasternal node-positive patients." | 3.70 | Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy. ( Kanno, M; Nakamura, S; Noguchi, M; Terasaki, Y; Tsugawa, K; Uotani, C; Yamanaka, S, 2000) |
| "We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i." | 3.69 | [Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997) |
| " Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present." | 3.69 | Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. ( Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994) |
| "Following local treatment and doxorubicin-containing standard chemotherapy, 42 patients with surgical Stage II or IIIA breast cancer containing ten or more involved axillary nodes and 13 patients with Stage IIIB disease were treated with high-dose chemotherapy (TMJ) consisting of thiotepa (750 mg/m2), mitoxantrone (40 mg/m2), and carboplatin (1000 mg/m2), with autologous bone marrow (ABM) and peripheral stem cell (PSC) transplant, followed by irradiation and/or hormone therapy." | 3.69 | TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer. ( Ahmed, T; Beer, M; Cook, P; Feldman, EJ; Lake, DE; Mittelman, A; Puccio, C; Razis, ED; Samonis, G, 1994) |
| "We undertook a phase I-II trail of loco-regional mitoxantrone in 12 patients affected by malignant gliomas." | 3.69 | Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. ( Boiardi, A; Broggi, G; Pozzi, A; Salmaggi, A; Silvani, A, 1996) |
| "To evaluate the clinical relevance of multidrug resistance (MDR) phenotype, the intracellular daunorubicin accumulation (IDA) and P-glycoprotein (P-gp) expression were investigated in 87 adult patients with acute leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with AML at relapse, and eight with secondary leukemia to myelodysplastic syndromes (MDS-AML)." | 3.69 | Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. ( Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F, 1995) |
| "Thirty-nine women (aged 31-82 years) with recurrent breast cancer underwent superselective IAC (25 mg/m2 mitoxantrone hydrochloride every 24 hours) through the subclavian artery branches after heparin administration." | 3.69 | Previously treated, locally recurrent breast cancer: treatment with superselective intraarterial chemotherapy. ( Brambs, HJ; Doma, A; Görich, J; Hasan, I; Kunze, V; Majdali, R; Reiser, M; Sittek, H, 1995) |
| "Fifty-three metastatic breast cancer patients were treated with a four-drug program of high-dose chemotherapy including cyclophosphamide (6 g/m2), thiotepa (500 mg/m2), carboplatin (800-1,600 mg/m2) and mitoxantrone (20-60 mg/m2) with autologous peripheral blood progenitor cell support followed by filgrastim." | 3.69 | [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer]. ( Alonso, JL; Ayala, F; Casado, A; Díaz-Rubio, E; Llorente, L; López Martín, JA; Martín, M; Nieto, Y; Pérez Calvo, J; Pérez López, C; Rodríguez Lescure, A; Villegas, A, 1997) |
| "Transcatheter arterial chemotherapy with mitoxantrone was carried out in 9 patients suffering from advanced breast cancer." | 3.68 | [Intra-arterial chemotherapy in locally advanced breast carcinomas]. ( Brambs, HJ; Görich, J; Kauffmann, GW; Kaufmann, M; Richter, GM; Roeren, T; Schmid, H, 1991) |
| "Forty-two patients with locally advanced breast cancer (n = 8) or recurrent breast cancer (n = 34) received regional chemotherapy (mitoxantrone 25 mg/m2 per 24 h) via the internal mammary artery or other vessels of the subclavian artery." | 3.68 | [Superselective intra-arterial chemotherapy in breast cancer]. ( Görich, J; Hartlapp, HJ; Hasan, I; Jakschik, J; Reiser, M; Sittek, H; Werner, H, 1993) |
| "Intensive sequential chemotherapy with mitoxantrone, 12 mg/m2/d on days 1 through 3, etoposide, 200 mg/m2/d as a continuous infusion on days 8 through 10, and cytarabine, 500 mg/m2/d as a continuous infusion on days 1 through 3 and 8 through 10 was administered to 72 patients aged less than 60 years with previously treated acute myelogenous leukemia (AML)." | 3.68 | Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. ( Archimbaud, E; Cordonnier, C; Devaux, Y; Dreyfus, F; Fenaux, P; Fiere, D; Jaubert, J; Leblond, V; Michallet, M; Travade, P, 1991) |
| "To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)." | 3.68 | A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990) |
| "The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed." | 3.67 | [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984) |
| "The effects of combination chemotherapy including mitoxantrone (MXN) "M-VEMFH" for advanced breast cancer were studied." | 3.67 | [Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer]. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sugiura, I, 1985) |
| "Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydrochloride)." | 3.66 | Mitoxantrone in patients with acute leukemia in relapse. ( Cuttner, J; Holland, JF; Ohnuma, T; Paciucci, PA; Silver, RT, 1983) |
| "The maximum tolerated dose of ixazomib in combination with MEC was 1." | 2.90 | A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. ( Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W, 2019) |
| "Current outcome of very early relapse of acute lymphoblastic leukemia (ALL) in children remains poor." | 2.82 | A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). ( Baruchel, A; Bertrand, Y; Brethon, B; Cave, H; Galambrun, C; Gandemer, V; Leverger, G; Nelken, B; Plat, G; Rohrlich, P; Schmitt, C; Thomas, C; Vérité, C, 2016) |
| "The results of this pilot trial suggest that more differentiated dosing schedules based on gender and bone marrow infiltration should be explored for rituximab therapy for lymphoma." | 2.77 | Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ( Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M, 2012) |
| "The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse." | 2.77 | A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. ( Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P, 2012) |
| "Gemcitabine (G) has shown activity in mantle cell lymphoma (MCL) as a single agent." | 2.74 | Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. ( Flynn, PJ; Garbo, LE; Kolibaba, KS; MacRae, MA; Rauch, MA; Wang, Y, 2009) |
| "This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML)." | 2.74 | Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. ( Chi, HS; Jang, S; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, SS; Lee, YS; Lim, SN; Park, CJ; Ryu, SG; Seol, M; Yun, SC, 2009) |
| "Primary resistant acute myeloid leukemia (AML) has a very poor prognosis." | 2.71 | Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. ( Chelghoum, Y; Elhamri, M; Le, QH; Michallet, M; Revesz, D; Thomas, X, 2003) |
| "The survival of patients with prostate cancer who relapse after androgen ablation is limited and the therapeutic options are restricted." | 2.71 | The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. ( Anagnostopoulos, A; Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kosmidis, P; Samelis, GF; Skarlos, D, 2003) |
| "Overall response rate was 31% in 26 acute myelogenous leukemia and 12." | 2.71 | Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ( Bauer, KS; Bible, K; Briel, J; Colevas, AD; Garimella, TS; Gojo, I; Gore, SD; Greer, J; Karp, JE; Kaufmann, S; Passaniti, A; Ross, DD; Smith, BD; Tidwell, ML; Wright, JJ, 2005) |
| "In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life." | 2.70 | 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001) |
| "One patient (1." | 2.68 | Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. ( Barraclough, B; Boyages, J; Langlands, AO; Ung, O, 1995) |
| "Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance." | 2.67 | Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994) |
| "Mitoxantrone is an active and relatively non-toxic agent which merits further assessment prior to its incorporation in first-line therapy of acute leukaemia." | 2.65 | Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1983) |
| "Recent advances have been made in the treatment of pancreas cancer." | 2.42 | [Adjuvant and additive therapy for cancer of the pancreas]. ( Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD, 2003) |
| "A 47 year old woman with a MALT lymphoma affecting the breast exclusively is reported." | 2.40 | [Primary MALT-type lymphoma of the breast]. ( Campo, E; Cervantes, F; Esteve, J; Montserrat, E; Rafel, M; Serra, A; Velasco, M, 1998) |
| "The term "hormone-refractory" prostate cancer has evolved to include patients with a spectrum of diseases." | 2.39 | Hormone-refractory (D3) prostate cancer: refining the concept. ( Kelly, WK; Scher, HI; Steineck, G, 1995) |
| "Bortezomib is a proteasome inhibitor with activity in pediatric acute lymphoblastic leukemia." | 1.56 | Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. ( August, KJ; Gamis, AS; Guest, EM; Hays, JA; Lewing, K, 2020) |
| "Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem cell transplantation (ASCT)." | 1.43 | High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. ( Aurer, I; Bašić-Kinda, S; Dotlić, S; Dujmović, D; Kralik, M; Labar, B; Mazić, S; Mitrović, Z; Nemet, D; Radman, I; Šantek, F; Sertić, D, 2016) |
| "There were 32 small lymphocytic lymphomas and 111 marginal zone lymphomas." | 1.42 | Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients. ( Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL, 2015) |
| "Multiple myeloma has low complete remission rate and high recurrence rate." | 1.33 | [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]. ( Hong, WD; Li, J; Luo, SK; Tong, XZ; Zhao, Y, 2005) |
| "A 28-year-old man with relapsed acute myelogenous leukemia (AML-M2) had undergone a non-myeloablative allogeneic peripheral stem cell transplantation." | 1.33 | Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. ( Kara, B; Kara, IO; Paydas, S; Sahin, B, 2005) |
| "Mitomycin C was administered initially and mitoxantrone was administered following the same schedule if disease recurred during followup." | 1.29 | Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. ( Carmignani, G; Maffezzini, M; Raber, M; Simonato, A; Zanon, M, 1996) |
| "Responses of the Hodgkin's disease to this therapy were favourable but short-lived." | 1.28 | High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Baglin, TP; Flavell, DJ; Flavell, SU; Lim, SH; Marcus, RE; Wimperis, JZ, 1992) |
| "Mitoxantrone is a substituted anthraquinone with considerable activity against human acute leukemia." | 1.28 | Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. ( Choi, KE; Daley, KM; Kaminer, LS; Larson, RA, 1990) |
| " The dosage of diaziquone was increased for sequential cohorts of seven patients from 20 mg/m2/day to 24 mg/m2/day, and finally to 28 mg/m2/day to determine the maximum tolerated dose for this chemotherapy combination." | 1.28 | Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. ( Amrein, PC; Davis, RB; Mayer, RJ; Schiffer, CA, 1990) |
| "Mitoxantrone was administered to 12 patients with advanced or recurrent endometrial carcinoma of whom only 1 had received prior chemotherapy (chlorambucil)." | 1.27 | Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma. ( Boadle, DJ; Tattersall, MH, 1987) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (10.14) | 18.7374 |
| 1990's | 60 (40.54) | 18.2507 |
| 2000's | 49 (33.11) | 29.6817 |
| 2010's | 21 (14.19) | 24.3611 |
| 2020's | 3 (2.03) | 2.80 |
| Authors | Studies |
|---|---|
| Kopmar, NE | 1 |
| Gooley, T | 1 |
| Curley, N | 1 |
| Russell, K | 1 |
| Shaw, C | 1 |
| Schonhoff, K | 1 |
| Lim, J | 1 |
| Halpern, AB | 1 |
| Walter, RB | 1 |
| Scott, BL | 1 |
| Appelbaum, J | 1 |
| Hendrie, PC | 1 |
| Estey, EH | 1 |
| Percival, MM | 1 |
| Peñalver, FJ | 1 |
| Márquez, JA | 1 |
| Durán, S | 1 |
| Giraldo, P | 1 |
| Martín, A | 1 |
| Montalbán, C | 1 |
| Sancho, JM | 1 |
| Ramírez, MJ | 1 |
| Terol, MJ | 1 |
| Capote, FJ | 1 |
| Gutiérrez, A | 1 |
| Sánchez, B | 1 |
| López, A | 1 |
| Salar, A | 1 |
| Rodríguez-Caravaca, G | 1 |
| Canales, M | 1 |
| Caballero, MD | 1 |
| August, KJ | 1 |
| Guest, EM | 1 |
| Lewing, K | 1 |
| Hays, JA | 1 |
| Gamis, AS | 1 |
| Ruan, M | 1 |
| Liu, LP | 1 |
| Zhang, AL | 1 |
| Quan Qi, B | 1 |
| Liu, F | 1 |
| Liu, TF | 1 |
| Liu, XM | 1 |
| Chen, XJ | 1 |
| Yang, WY | 1 |
| Guo, Y | 1 |
| Zhang, L | 1 |
| Zou, Y | 1 |
| Chen, YM | 1 |
| Zhu, XF | 1 |
| Nakamura, S | 2 |
| Kawaguchi, K | 1 |
| Fukui, T | 1 |
| Hakiri, S | 1 |
| Ozeki, N | 1 |
| Mori, S | 1 |
| Goto, M | 1 |
| Hashimoto, K | 1 |
| Ito, T | 1 |
| Yokoi, K | 1 |
| Advani, AS | 1 |
| Cooper, B | 1 |
| Visconte, V | 1 |
| Elson, P | 1 |
| Chan, R | 1 |
| Carew, J | 1 |
| Wei, W | 1 |
| Mukherjee, S | 1 |
| Gerds, A | 1 |
| Carraway, H | 1 |
| Nazha, A | 1 |
| Hamilton, B | 1 |
| Sobecks, R | 2 |
| Caimi, P | 1 |
| Tomlinson, B | 1 |
| Malek, E | 1 |
| Little, J | 1 |
| Miron, A | 1 |
| Pink, J | 1 |
| Maciejewski, J | 1 |
| Unger, A | 1 |
| Kalaycio, M | 2 |
| de Lima, M | 1 |
| Sekeres, MA | 2 |
| Lafrenie, RM | 1 |
| Speigl, L | 1 |
| Buckner, CA | 1 |
| Pawelec, G | 1 |
| Conlon, MS | 1 |
| Shipp, C | 1 |
| Lowry, L | 1 |
| Smith, P | 1 |
| Cunningham, D | 1 |
| Linch, DC | 1 |
| Zinzani, PL | 1 |
| Pellegrini, C | 1 |
| Broccoli, A | 1 |
| Gandolfi, L | 1 |
| Stefoni, V | 1 |
| Casadei, B | 1 |
| Maglie, R | 1 |
| Argnani, L | 1 |
| Pileri, S | 2 |
| Thiel, A | 1 |
| Schetelig, J | 1 |
| Pönisch, W | 1 |
| Schäfer-Eckart, K | 1 |
| Aulitzky, W | 1 |
| Peter, N | 1 |
| Schulze, A | 1 |
| Maschmeyer, G | 2 |
| Neugebauer, S | 1 |
| Herbst, R | 2 |
| Hänel, A | 2 |
| Morgner, A | 1 |
| Kroschinsky, F | 2 |
| Bornhäuser, M | 1 |
| Lange, T | 1 |
| Wilhelm, M | 1 |
| Niederwieser, D | 1 |
| Ehninger, G | 2 |
| Fiedler, F | 2 |
| Hänel, M | 2 |
| Cohen, JB | 1 |
| Bucur, S | 1 |
| Winton, EF | 1 |
| Sinha, R | 1 |
| Heffner, LT | 1 |
| King, N | 1 |
| Lonial, S | 1 |
| Langston, AA | 1 |
| Waller, EK | 1 |
| Hutchison-Rzepka, A | 1 |
| Colbert, A | 1 |
| Lechowicz, MJ | 1 |
| Flowers, CR | 1 |
| Nelken, B | 1 |
| Cave, H | 1 |
| Leverger, G | 1 |
| Galambrun, C | 1 |
| Plat, G | 1 |
| Schmitt, C | 1 |
| Thomas, C | 1 |
| Vérité, C | 1 |
| Brethon, B | 1 |
| Gandemer, V | 1 |
| Bertrand, Y | 1 |
| Baruchel, A | 1 |
| Rohrlich, P | 1 |
| Aurer, I | 1 |
| Nemet, D | 1 |
| Mitrović, Z | 1 |
| Dujmović, D | 1 |
| Bašić-Kinda, S | 1 |
| Radman, I | 1 |
| Sertić, D | 1 |
| Šantek, F | 1 |
| Kralik, M | 1 |
| Dotlić, S | 1 |
| Mazić, S | 1 |
| Labar, B | 1 |
| Tang, YL | 1 |
| Chia, WK | 1 |
| Yap, EC | 1 |
| Julia, MI | 1 |
| Leong, CF | 1 |
| Salwati, S | 1 |
| Wong, CL | 1 |
| Rashed, WM | 1 |
| Zekri, W | 1 |
| Awad, M | 1 |
| Taha, H | 1 |
| Abdalla, B | 1 |
| Alfaar, AS | 1 |
| Lee, SS | 1 |
| Lee, JH | 2 |
| Kim, DY | 1 |
| Kim, SH | 1 |
| Lim, SN | 1 |
| Lee, YS | 1 |
| Seol, M | 1 |
| Ryu, SG | 1 |
| Kang, YA | 1 |
| Jang, S | 1 |
| Park, CJ | 1 |
| Chi, HS | 1 |
| Yun, SC | 1 |
| Lee, KH | 1 |
| Garbo, LE | 1 |
| Flynn, PJ | 1 |
| MacRae, MA | 1 |
| Rauch, MA | 1 |
| Wang, Y | 1 |
| Kolibaba, KS | 1 |
| Hogg, ME | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Brady, AK | 1 |
| Fu, AZ | 1 |
| Earl, M | 1 |
| Advani, A | 1 |
| Saunthararajah, Y | 1 |
| Copelan, E | 1 |
| Eom, KS | 1 |
| Min, WS | 1 |
| Kim, HJ | 1 |
| Cho, BS | 1 |
| Choi, SM | 1 |
| Lee, DG | 1 |
| Lee, S | 1 |
| Min, CK | 1 |
| Kim, YJ | 1 |
| Cho, SG | 1 |
| Lee, JW | 1 |
| Kim, CC | 1 |
| Wei, A | 1 |
| Teh, TC | 1 |
| Price, SL | 1 |
| Lancet, JE | 1 |
| George, TJ | 1 |
| Wetzstein, GA | 1 |
| List, AF | 2 |
| Ho, VQ | 1 |
| Fernandez, HF | 1 |
| Pinilla-Ibarz, J | 1 |
| Kharfan-Dabaja, MA | 1 |
| Komrokji, RS | 1 |
| Machaczka, M | 1 |
| Nahi, H | 1 |
| Karbach, H | 1 |
| Klimkowska, M | 1 |
| Hägglund, H | 1 |
| Molitor, B | 1 |
| Börgermann, C | 1 |
| Uy, GL | 1 |
| Rettig, MP | 1 |
| Motabi, IH | 1 |
| McFarland, K | 1 |
| Trinkaus, KM | 1 |
| Hladnik, LM | 1 |
| Kulkarni, S | 1 |
| Abboud, CN | 1 |
| Cashen, AF | 1 |
| Stockerl-Goldstein, KE | 1 |
| Vij, R | 1 |
| Westervelt, P | 1 |
| DiPersio, JF | 1 |
| Jäger, U | 1 |
| Fridrik, M | 1 |
| Zeitlinger, M | 1 |
| Heintel, D | 1 |
| Hopfinger, G | 1 |
| Burgstaller, S | 1 |
| Mannhalter, C | 1 |
| Oberaigner, W | 1 |
| Porpaczy, E | 1 |
| Skrabs, C | 1 |
| Einberger, C | 1 |
| Drach, J | 1 |
| Raderer, M | 1 |
| Gaiger, A | 1 |
| Putman, M | 1 |
| Greil, R | 1 |
| Filleron, T | 1 |
| Kramar, A | 1 |
| Dalenc, F | 1 |
| Spielmann, M | 1 |
| Fumoleau, P | 1 |
| Kerbrat, P | 1 |
| Martin, AL | 1 |
| Roché, H | 1 |
| Büchler, T | 1 |
| Ferra, C | 1 |
| Virgili, N | 1 |
| Montanya, E | 1 |
| Grañena, A | 1 |
| Neoptolemos, JP | 1 |
| Raraty, MG | 1 |
| Ghaneh, P | 1 |
| Hickey, H | 1 |
| Stocken, DD | 1 |
| Dunn, JA | 1 |
| Friess, H | 1 |
| Büchler, MW | 1 |
| Huang, JS | 1 |
| Chen, WH | 1 |
| Lin, CC | 1 |
| Liaw, CC | 1 |
| Wang, CH | 1 |
| Lan, YJ | 1 |
| Lai, CH | 1 |
| Liu, JP | 1 |
| Katsumata, K | 2 |
| Tomioka, H | 1 |
| Kusama, M | 2 |
| Aoki, T | 1 |
| Koyanagi, Y | 2 |
| Samelis, GF | 1 |
| Skarlos, D | 1 |
| Bafaloukos, D | 1 |
| Kosmidis, P | 1 |
| Anagnostopoulos, A | 1 |
| Aravantinos, G | 1 |
| Dimopoulos, MA | 1 |
| Revesz, D | 1 |
| Chelghoum, Y | 2 |
| Le, QH | 1 |
| Elhamri, M | 2 |
| Michallet, M | 3 |
| Thomas, X | 2 |
| Ring, A | 1 |
| Webb, A | 1 |
| Ashley, S | 2 |
| Allum, WH | 1 |
| Ebbs, S | 2 |
| Gui, G | 1 |
| Sacks, NP | 1 |
| Walsh, G | 2 |
| Smith, IE | 1 |
| Bassi, PF | 1 |
| Spinadin, R | 1 |
| Carando, R | 1 |
| Dal Moro, F | 1 |
| Abatangelo, G | 1 |
| Piazza, N | 1 |
| Tavolini, IM | 1 |
| Calais, G | 4 |
| Papatsoris, AG | 1 |
| Deliveliotis, C | 1 |
| Giannopoulos, A | 1 |
| Dimopoulos, C | 1 |
| Boiardi, A | 8 |
| Bartolomei, M | 2 |
| Silvani, A | 7 |
| Eoli, M | 6 |
| Salmaggi, A | 7 |
| Lamperti, E | 4 |
| Milanesi, I | 2 |
| Botturi, A | 4 |
| Rocca, P | 1 |
| Bodei, L | 1 |
| Broggi, G | 8 |
| Paganelli, G | 1 |
| Le, Q | 1 |
| Botton, Sd | 1 |
| Raffoux, E | 1 |
| Pautas, C | 1 |
| Dreyfus, F | 2 |
| Dhedin, N | 1 |
| Vekhoff, A | 1 |
| Troncy, J | 1 |
| Pigneux, A | 1 |
| Revel, Td | 1 |
| Reman, O | 1 |
| Travade, P | 2 |
| Thiebaut, A | 1 |
| Guerci, A | 2 |
| Fenaux, P | 2 |
| Dombret, H | 1 |
| Kara, IO | 1 |
| Sahin, B | 1 |
| Paydas, S | 1 |
| Kara, B | 1 |
| Bao, L | 1 |
| Jiang, B | 1 |
| Huang, XJ | 1 |
| Wang, DB | 1 |
| Qiu, JY | 1 |
| Lu, XJ | 1 |
| Lu, J | 1 |
| Shi, HX | 1 |
| Wang, FR | 1 |
| Lu, DP | 1 |
| Bissola, L | 1 |
| Finocchiaro, G | 1 |
| Karp, JE | 2 |
| Passaniti, A | 1 |
| Gojo, I | 1 |
| Kaufmann, S | 1 |
| Bible, K | 1 |
| Garimella, TS | 1 |
| Greer, J | 2 |
| Briel, J | 2 |
| Smith, BD | 2 |
| Gore, SD | 2 |
| Tidwell, ML | 1 |
| Ross, DD | 1 |
| Wright, JJ | 2 |
| Colevas, AD | 2 |
| Bauer, KS | 1 |
| Luo, SK | 1 |
| Li, J | 1 |
| Hong, WD | 1 |
| Zhao, Y | 1 |
| Tong, XZ | 1 |
| Rouëssé, J | 1 |
| de la Lande, B | 1 |
| Bertheault-Cvitkovic, F | 1 |
| Serin, D | 3 |
| Graïc, Y | 1 |
| Combe, M | 1 |
| Leduc, B | 1 |
| Lucas, V | 1 |
| Demange, L | 1 |
| Nguyen, TD | 1 |
| Castèra, D | 1 |
| Krzisch, C | 1 |
| Villet, R | 1 |
| Mouret-Fourme, E | 1 |
| Garbay, JR | 1 |
| Noguès, C | 1 |
| Nakabayashi, M | 1 |
| Oh, WK | 1 |
| Toledano, A | 2 |
| Garaud, P | 2 |
| Fourquet, A | 2 |
| Bosset, JF | 2 |
| Breteau, N | 1 |
| Body, G | 2 |
| Azria, D | 2 |
| Le Floch, O | 3 |
| Ferroli, P | 1 |
| Broggi, M | 1 |
| Franzini, A | 1 |
| Maccagnano, E | 1 |
| Lamperti, M | 1 |
| Niitsu, N | 2 |
| Kohori, M | 1 |
| Higashihara, M | 1 |
| Bessho, M | 1 |
| Miny-Buffet, J | 1 |
| Favre, A | 1 |
| Mathew, J | 1 |
| Asgeirsson, KS | 1 |
| Agrawal, A | 1 |
| Mukherjee, A | 1 |
| Ellis, IO | 1 |
| Cheung, KL | 2 |
| Chan, SY | 2 |
| Robertson, JF | 2 |
| Levis, MJ | 1 |
| Hattenburg, C | 1 |
| Jones, RJ | 1 |
| Isogai, R | 1 |
| Fukao, M | 1 |
| Kawada, A | 1 |
| Izumi, K | 1 |
| Kanno, H | 1 |
| Umemoto, S | 1 |
| Hasumi, H | 1 |
| Osada, Y | 1 |
| Otai, J | 1 |
| Mikata, K | 1 |
| Tsuchiya, F | 1 |
| Nagashima, Y | 1 |
| Lü, SQ | 1 |
| Yang, JM | 1 |
| Song, XM | 1 |
| Chen, L | 1 |
| Zhang, WP | 1 |
| Ni, X | 1 |
| Xu, XQ | 1 |
| Wang, JM | 1 |
| Gaviani, P | 1 |
| Fiumani, A | 1 |
| Falcone, C | 1 |
| Solari, A | 1 |
| Filippini, G | 1 |
| Di Meco, F | 1 |
| Prentice, HG | 1 |
| Robbins, G | 1 |
| Ma, DD | 1 |
| Ho, AD | 1 |
| Tominaga, T | 1 |
| Kitamura, M | 1 |
| Hayashi, K | 1 |
| Takahashi, I | 1 |
| Kosaki, G | 1 |
| Paciucci, PA | 1 |
| Ohnuma, T | 1 |
| Cuttner, J | 1 |
| Silver, RT | 1 |
| Holland, JF | 1 |
| Maffezzini, M | 1 |
| Simonato, A | 1 |
| Zanon, M | 1 |
| Raber, M | 1 |
| Carmignani, G | 1 |
| Merlin, JL | 1 |
| Missoum, N | 1 |
| Feldmann, L | 1 |
| Marchal, S | 1 |
| Witz, F | 1 |
| Rose, C | 2 |
| Guerci, O | 1 |
| Görich, J | 4 |
| Hasan, I | 2 |
| Majdali, R | 1 |
| Sittek, H | 2 |
| Kunze, V | 2 |
| Doma, A | 1 |
| Reiser, M | 2 |
| Brambs, HJ | 3 |
| Namasivayam, S | 1 |
| Whelan, P | 1 |
| Scher, HI | 1 |
| Steineck, G | 1 |
| Kelly, WK | 1 |
| Lob, S | 1 |
| Bergmann, L | 1 |
| Müller, H | 1 |
| Jacobi, V | 1 |
| Hoelzer, D | 1 |
| Flamm, J | 1 |
| Donner, G | 1 |
| Oberleitner, S | 1 |
| Hausmann, R | 1 |
| Havelec, L | 1 |
| Doughty, JC | 1 |
| McCarter, DH | 1 |
| Reid, AW | 1 |
| Kane, E | 1 |
| McArdle, CS | 1 |
| Stiff, P | 1 |
| Bayer, R | 1 |
| Camarda, M | 1 |
| Tan, S | 1 |
| Dolan, J | 1 |
| Potkul, R | 1 |
| Loutfi, S | 1 |
| Kinch, L | 1 |
| Sosman, J | 1 |
| Peace, D | 1 |
| Iba, T | 1 |
| Yagi, Y | 2 |
| Kidokoro, A | 1 |
| Fukunaga, M | 1 |
| Momose, F | 1 |
| Ung, O | 1 |
| Langlands, AO | 1 |
| Barraclough, B | 1 |
| Boyages, J | 1 |
| Razis, ED | 1 |
| Samonis, G | 1 |
| Cook, P | 1 |
| Beer, M | 1 |
| Mittelman, A | 1 |
| Lake, DE | 1 |
| Feldman, EJ | 1 |
| Puccio, C | 1 |
| Ahmed, T | 1 |
| Berger, C | 1 |
| Descamps, P | 1 |
| Chapet, S | 1 |
| Reynaud-Bougnoux, A | 1 |
| Bougnoux, P | 1 |
| Lansac, J | 1 |
| Cabanillas, F | 3 |
| Rodriguez, MA | 1 |
| Hagemeister, FB | 2 |
| Purugganan, R | 1 |
| Fuller, L | 1 |
| McLaughlin, P | 1 |
| Swan, F | 1 |
| Romaguera, J | 1 |
| Rodriguez, M | 1 |
| Mäenpää, J | 1 |
| Kivinen, S | 1 |
| Räisänen, I | 1 |
| Sipilä, P | 1 |
| Väyrynen, M | 1 |
| Gröhn, P | 1 |
| Dufour, P | 1 |
| Bergerat, JP | 1 |
| Barats, JC | 1 |
| Giron, C | 1 |
| Duclos, B | 1 |
| Dellenbach, P | 1 |
| Ritter, J | 1 |
| Renaud, R | 1 |
| Audhuy, B | 1 |
| Oberling, F | 1 |
| Cherqui, D | 1 |
| Piedbois, P | 1 |
| Pierga, JY | 1 |
| Duvoux, C | 1 |
| Vavasseur, D | 1 |
| Tran Van-Nhieu, J | 1 |
| LeBourgeois, JP | 1 |
| Julien, M | 1 |
| Fagniez, PL | 1 |
| Dhumeaux, D | 1 |
| Lorusso, V | 1 |
| Catino, A | 1 |
| Gargano, G | 1 |
| Fioretto, A | 1 |
| Berardi, F | 1 |
| de Lena, M | 1 |
| Serretta, V | 1 |
| Corselli, G | 1 |
| Pavone, C | 1 |
| Pavone-Macaluso, M | 1 |
| Tarraza, HM | 1 |
| Boyce, CR | 1 |
| Smith, WG | 1 |
| Jones, MA | 1 |
| Jakschik, J | 1 |
| Werner, H | 1 |
| Hartlapp, HJ | 1 |
| Newling, DW | 1 |
| Brensing, KA | 1 |
| Sokiranski, R | 1 |
| Rilinger, N | 1 |
| Müller-Miny, H | 1 |
| van Bree, C | 1 |
| Schopman, EM | 1 |
| Bakker, PJ | 1 |
| Kipp, JB | 1 |
| Barendsen, GW | 1 |
| Spier, CS | 1 |
| Grogan, TM | 1 |
| Johnson, C | 1 |
| Roe, DJ | 1 |
| Greer, JP | 1 |
| Wolff, SN | 1 |
| Broxterman, HJ | 1 |
| Scheffer, GL | 2 |
| Scheper, RJ | 2 |
| Dalton, WS | 1 |
| Haas, R | 1 |
| Moos, M | 1 |
| Möhle, R | 1 |
| Döhner, H | 1 |
| Witt, B | 1 |
| Goldschmidt, H | 1 |
| Murea, S | 1 |
| Flentje, M | 1 |
| Wannenmacher, M | 1 |
| Hunstein, W | 1 |
| Salutari, P | 1 |
| Micciulli, G | 1 |
| Chiusolo, P | 1 |
| Tommasi, M | 1 |
| Di Mario, A | 1 |
| Sica, S | 1 |
| Leone, G | 1 |
| Pozzi, A | 2 |
| Aasebø, U | 1 |
| Norum, J | 1 |
| Sager, G | 1 |
| Slørdal, L | 1 |
| Abubakar, AA | 1 |
| Riches, AC | 1 |
| Kahles, H | 1 |
| Bastian, HJ | 1 |
| Schiffmann, O | 1 |
| Geck, M | 1 |
| Helmke, FR | 1 |
| Golz, N | 1 |
| Hartmann, KA | 1 |
| Audretsch, W | 1 |
| Carl, UM | 1 |
| Gripp, S | 1 |
| Kolotas, C | 1 |
| Muskalla, K | 1 |
| Rezai, M | 1 |
| Schnabel, T | 2 |
| Waap, I | 1 |
| Zamboglou, N | 2 |
| Schmitt, G | 2 |
| Gondo, H | 1 |
| Harada, M | 1 |
| Miyamoto, T | 1 |
| Takenaka, K | 1 |
| Tanimoto, K | 1 |
| Mizuno, S | 1 |
| Fujisaki, T | 1 |
| Nagafuji, K | 1 |
| Hayashi, S | 1 |
| Eto, T | 1 |
| Taniguchi, S | 1 |
| Akashi, K | 1 |
| Harada, N | 1 |
| Yamasaki, K | 1 |
| Shibuya, T | 1 |
| Matsuishi, E | 1 |
| Ohno, Y | 1 |
| Makino, S | 1 |
| Takamatsu, Y | 1 |
| Murakawa, M | 1 |
| Teshima, T | 1 |
| Hirota, Y | 1 |
| Okamura, T | 1 |
| Kinukawa, N | 1 |
| Niho, Y | 1 |
| Yamamoto, K | 1 |
| Shibata, K | 1 |
| Murano, A | 1 |
| Kawasaki, M | 1 |
| Moriwaki, R | 1 |
| Nagakawa, Y | 1 |
| Ogata, T | 1 |
| Ellis, P | 1 |
| Smith, I | 1 |
| Baum, M | 1 |
| Sacks, N | 1 |
| McKinna, J | 1 |
| Martín, M | 1 |
| Casado, A | 1 |
| Llorente, L | 1 |
| López Martín, JA | 1 |
| Rodríguez Lescure, A | 1 |
| Nieto, Y | 1 |
| Ayala, F | 1 |
| Pérez Calvo, J | 1 |
| Alonso, JL | 1 |
| Pérez López, C | 1 |
| Villegas, A | 1 |
| Díaz-Rubio, E | 1 |
| Rafel, M | 1 |
| Esteve, J | 1 |
| Cervantes, F | 1 |
| Velasco, M | 1 |
| Serra, A | 1 |
| Campo, E | 1 |
| Montserrat, E | 1 |
| Sanna, P | 1 |
| Van den Bosch, S | 1 |
| Cavalli, F | 1 |
| Ghielmini, M | 1 |
| Robak, T | 1 |
| Gora-Tybor, J | 1 |
| Urbańska-Ryś, H | 1 |
| Krykowski, E | 1 |
| Husain, A | 1 |
| Sabbatini, P | 1 |
| Spriggs, D | 1 |
| Fennelly, D | 1 |
| Aghajanian, C | 1 |
| Barakat, R | 1 |
| Curtin, J | 1 |
| Venkatraman, E | 1 |
| Hoskins, W | 3 |
| Markman, M | 3 |
| Sternberg, DW | 1 |
| Aird, W | 1 |
| Neuberg, D | 1 |
| Thompson, L | 1 |
| MacNeill, K | 1 |
| Amrein, P | 1 |
| Shulman, LN | 1 |
| Matsuoka, T | 1 |
| Nomizu, T | 1 |
| Yabuta, T | 1 |
| Katagata, N | 1 |
| Watanabe, F | 1 |
| Yamaki, Y | 1 |
| Tsuchiya, A | 1 |
| Takenoshita, S | 1 |
| Eilber, FC | 1 |
| Rosen, G | 1 |
| Forscher, C | 1 |
| Nelson, SD | 1 |
| Dorey, F | 1 |
| Eilber, FR | 1 |
| Kanno, M | 1 |
| Uotani, C | 1 |
| Yamanaka, S | 1 |
| Terasaki, Y | 1 |
| Tsugawa, K | 1 |
| Noguchi, M | 1 |
| Sato , K | 1 |
| Hiraide, H | 1 |
| Tamakuma, S | 1 |
| Tabei, T | 1 |
| Maruyama, M | 1 |
| Touma, M | 1 |
| Okamura, H | 1 |
| Matsumoto, F | 1 |
| Akao, S | 1 |
| Ishikawa, H | 1 |
| Mochizuki, H | 1 |
| Ruiz Hernández, G | 1 |
| Pallardó-Calatayud, J | 1 |
| Ferrer Albiach, C | 1 |
| Balaguer-Martínez, JV | 1 |
| Romero-de-Avila, C | 1 |
| Castillo-Pallarés, FJ | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 2 |
| Burian, M | 2 |
| Gedlicka, C | 2 |
| Selzer, E | 2 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 2 |
| Kröger, N | 1 |
| Birkmann, J | 1 |
| Naumann, R | 1 |
| Friedrichsen, K | 1 |
| Zander, AR | 1 |
| Iijima, K | 1 |
| Chizuka, A | 1 |
| DiPaola, RS | 1 |
| Chenven, ES | 1 |
| Shih, WJ | 1 |
| Lin, Y | 1 |
| Amenta, P | 1 |
| Goodin, S | 1 |
| Shumate, A | 1 |
| Capanna, T | 1 |
| Cardiella, M | 1 |
| Cummings, KB | 1 |
| Aisner, J | 1 |
| Todd, MB | 1 |
| Tan, SM | 1 |
| Willsher, PC | 1 |
| Blamey, RW | 1 |
| Zappacosta, B | 1 |
| Fariselli, L | 1 |
| Wilder, RB | 1 |
| Schlembach, PJ | 1 |
| Jones, D | 1 |
| Chronowski, GM | 1 |
| Ha, CS | 1 |
| Younes, A | 1 |
| Barista, I | 1 |
| Cox, JD | 1 |
| van der Kolk, DM | 1 |
| Vellenga, E | 1 |
| Müller, M | 1 |
| Bates, SE | 1 |
| de Vries, EG | 1 |
| Schüll, B | 1 |
| Formanek, M | 1 |
| Knerer, B | 1 |
| Scheithauer, W | 1 |
| Chisesi, T | 1 |
| Federico, M | 1 |
| Levis, A | 1 |
| Deliliers, GL | 1 |
| Gobbi, PG | 1 |
| Santini, G | 1 |
| Luminari, S | 1 |
| Linfomi, MB | 1 |
| Michieli, M | 1 |
| Damiani, D | 1 |
| Geromin, A | 1 |
| Michelutti, A | 1 |
| Fanin, R | 1 |
| Raspadori, D | 1 |
| Russo, D | 1 |
| Visani, G | 1 |
| Dinota, A | 1 |
| Saglik, Y | 1 |
| Icli, F | 1 |
| Uluoglu, O | 1 |
| Isiklar, ZU | 1 |
| Lim, SH | 1 |
| Baglin, TP | 1 |
| Flavell, DJ | 1 |
| Flavell, SU | 1 |
| Wimperis, JZ | 1 |
| Marcus, RE | 1 |
| Liso, V | 1 |
| Specchia, G | 1 |
| Capalbo, S | 1 |
| Pavone, V | 1 |
| Iacobazzi, A | 1 |
| Iaculli, ML | 1 |
| Dione, R | 1 |
| Pansini, N | 1 |
| Schmid, H | 1 |
| Roeren, T | 1 |
| Richter, GM | 1 |
| Kaufmann, M | 1 |
| Kauffmann, GW | 1 |
| Merk, K | 1 |
| Ideström, K | 1 |
| Johansson, B | 1 |
| Kimby, E | 1 |
| Lindemalm, C | 1 |
| Osby, E | 1 |
| Björkholm, M | 1 |
| Archimbaud, E | 1 |
| Leblond, V | 1 |
| Cordonnier, C | 1 |
| Jaubert, J | 1 |
| Devaux, Y | 1 |
| Fiere, D | 1 |
| Hakes, T | 2 |
| Reichman, B | 2 |
| Lewis, JL | 2 |
| Rubin, S | 2 |
| Jones, W | 2 |
| Almadrones, L | 1 |
| Fornasiero, A | 1 |
| Daniele, O | 1 |
| Ghiotto, C | 1 |
| Piazza, M | 1 |
| Fiore-Donati, L | 1 |
| Calabró, F | 1 |
| Rea, F | 1 |
| Fiorentino, MV | 1 |
| Wallerstein, R | 1 |
| Spitzer, G | 1 |
| Dunphy, F | 1 |
| Huan, S | 1 |
| Hortobagyi, G | 1 |
| Yau, J | 1 |
| Buzdar, A | 1 |
| Holmes, F | 1 |
| Theriault, R | 1 |
| Ewer, M | 1 |
| Muss, HB | 1 |
| Bundy, BN | 1 |
| Adcock, L | 1 |
| Beecham, J | 1 |
| Kober, F | 1 |
| Heiss, A | 1 |
| Keminger, K | 1 |
| Depisch, D | 1 |
| Hiddemann, W | 1 |
| Aul, HC | 1 |
| Urbanitz, D | 1 |
| Lathan, B | 1 |
| Reichle, A | 1 |
| Köppler, H | 1 |
| Donhuijsen-Ant, R | 1 |
| Ludwig, WD | 1 |
| Grüneisen, T | 1 |
| Stewart, DJ | 2 |
| Green, R | 1 |
| Futter, N | 1 |
| Walsh, W | 1 |
| McKay, D | 1 |
| Verma, S | 1 |
| Maroun, JA | 2 |
| Redmond, D | 1 |
| Marit, G | 1 |
| Cony, P | 1 |
| Duclos, F | 1 |
| Puntous, M | 1 |
| Broustet, A | 1 |
| Reiffers, J | 1 |
| Kaminer, LS | 1 |
| Choi, KE | 1 |
| Daley, KM | 1 |
| Larson, RA | 1 |
| Amrein, PC | 1 |
| Davis, RB | 1 |
| Mayer, RJ | 1 |
| Schiffer, CA | 1 |
| Kuhn, K | 1 |
| Purea, H | 1 |
| Selbach, J | 1 |
| Westerhausen, M | 1 |
| Evensen, SA | 1 |
| Brinch, L | 1 |
| Wisløff, F | 1 |
| Werner, A | 1 |
| Diedrich, K | 1 |
| Krebs, D | 1 |
| Bode, U | 1 |
| Musch, E | 1 |
| Boadle, DJ | 1 |
| Tattersall, MH | 1 |
| Taguchi, T | 1 |
| Sakai, K | 1 |
| Terasawa, T | 1 |
| Wada, H | 1 |
| Charrot, P | 1 |
| Chevrier, A | 1 |
| Cripps, C | 1 |
| Hilgers, RD | 1 |
| Von Hoff, DD | 1 |
| Stephens, RL | 1 |
| Boutselis, JG | 1 |
| Hørding, U | 1 |
| Jakobsen, K | 1 |
| Dirksen, H | 1 |
| Buzdar, AU | 1 |
| Marcus, C | 1 |
| Smith, TL | 1 |
| Blumenschein, GR | 1 |
| Ito, Y | 1 |
| Hoshino, A | 1 |
| Ohara, K | 1 |
| Kamiya, O | 1 |
| Nagata, K | 1 |
| Kojima, T | 1 |
| Kinoshita, T | 1 |
| Sugiura, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed[NCT01133158] | Phase 2 | 61 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability[NCT00208975] | Phase 2 | 15 participants (Actual) | Interventional | 2002-07-31 | Terminated (stopped due to slow accrual) | ||
| an Single Center，Single Arm, Phase 3 Study to Evaluate Efficacy and Safety of PD-1 Inhibitor Combined With Azacytidine and HAG Regimen for Patients With Relapsed or Refractory Acute Myeloid Leukemia.[NCT04722952] | Phase 3 | 30 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study[NCT02605460] | Phase 2 | 20 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML[NCT00512252] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Multicenter Study to Evaluate the Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy Und Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma[NCT01560117] | Phase 2 | 29 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma[NCT00002474] | Phase 2 | 0 participants | Interventional | 1991-02-28 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint is the number of Participants with Response according to the criteria of the International Workshop to Standardize Response Criteria for NHL~Complete Remission (CR):~Nodes returned to normal (if GTD >15 mm before therapy, GTD now ≤15 mm; if GTD 11-15 and SA >10 mm before therapy, SA now ≤10 mm) All (non-nodal) target lesions completely resolved~Partial Remission (PR) SPD of target lesions decreased ≥50% from baseline Spleen and liver nodules regress by 50% in SPD or single lesion in GTD~Stable Disease (SD) Not enough shrinkage for PR Not enough growth for PD~Progressive Disease (PD):~SPD increase ≥50% from nadir (smallest value seen during trial) in nodal target lesions overall or in any single nodal target lesion" (NCT01133158)
Timeframe: 7 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Induction Rituximab, Bendamustine, Mitoxantrone, Dexamethasone | 57 |
| Maintenance Rituximab | 35 |
(NCT01133158)
Timeframe: 7 years
| Intervention | months (Median) | |||
|---|---|---|---|---|
| Progression-Free Survival | Disease-Free Survival | Global Survival | Duration of the Response | |
| R-BMD | 56 | 51 | NA | 54 |
"Complete Response (CR): Disappearance of all clinical evidence of active tumor for a minimum of eight weeks and absence of any symptoms related to the tumor.~Partial Response (PR):50% decrease in the sum of the product diameters of all lesions that persist for at least four weeks. No lesion can increase in size and no new lesion can appear during this period.~Stable disease (SD):A tumor that is neither growing nor shrinking.No new tumors have developed" (NCT00208975)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | |
| Chronic Lymphocytic Leukemia | 4 | 2 | 1 |
| Non Hodgkin Lymphoma | 5 | 2 | 0 |
(NCT00512252)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II Dose Treatment | 37 |
A standard 3+3 design was used in the Phase I portion starting with the AMD3100 dose of 80 mcg/kg and escalating by 80 mcg/kg for each successive cohort up to a maximum of 240 mcg/kg/d. The optimal dose was defined as the highest dose of AMD3100 <= 240 mcg/kg at which 0-1 of 6 patients experienced a dose limiting toxicity. (NCT00512252)
Timeframe: Completion of all patients in Phase I portion (232 days)
| Intervention | mcg/kg (Number) |
|---|---|
| Phase I Dose Escalation | 240 |
"This is determined only for patients achieving a complete remission. Defined as the interval from the date of the first documentation of a leukemia free state to date of recurrence or death due to any cause.~Kaplain-Meier estimate was used." (NCT00512252)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II Dose Treatment | 42.9 |
Defined as the date of the first dose of AMD3100 to the date that the absolute neutrophil count >1,000 cells/mm^3. (NCT00512252)
Timeframe: 42 days
| Intervention | days (Median) |
|---|---|
| Phase II Dose Treatment | 28 |
Defined as the date of the first dose of AMD3100 to the date that the platelet count is >100,000/mm3 in the absence of platelet transfusions. (NCT00512252)
Timeframe: 42 days
| Intervention | days (Median) |
|---|---|
| Phase II Dose Treatment | 28.5 |
Measured at 0 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after AMD3100 dose on Day 0. (NCT00512252)
Timeframe: Day 0
| Intervention | percentage of AML blasts (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| AML blasts at 0 hours | AML blasts at 1 hour | AML blasts at 2 hours | AML blasts at 4 hours | AML blasts at 6 hours | AML blasts at 8 hours | AML blasts at 12 hours | AML blasts at 24 hours | |
| Phase I Dose Escalation - Dose Level 1 | 46.0 | 26.0 | 26.0 | 37.0 | 31.0 | 32.0 | 27.0 | 35.0 |
| Phase I Dose Escalation - Dose Level 2 | 4.0 | 9.0 | 37.5 | 16.0 | 14.0 | 19.0 | 45.0 | 23 |
| Phase I Dose Escalation - Dose Level 3 | 43.5 | 30.5 | 32.5 | 30.0 | 27.0 | 26.0 | 35.0 | 55 |
"Measured at 0 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after AMD3100 dose on Day 0.~Characterization of the mobilized cells as well as the kinetics of mobilization will be determined by analyzing the surface expression of mobilized cells by flow cytometry at the specified time points in conjunction with their total leukocyte count from the patient's CBC." (NCT00512252)
Timeframe: Day 0
| Intervention | cells x 10^3/microliter (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total leukocytes at 0 hours | Total leukocytes at 1 hour | Total leukocytes at 2 hours | Total leukocytes at 4 hours | Total leukocytes at 6 hours | Total leukocytes at 8 hours | Total leukocytes at 12 hours | Total leukocytes at 24 hours | |
| Phase I Dose Escalation - Dose Level 1 | 2.5 | 4.3 | 4 | 4.7 | 4.8 | 4.5 | 5.1 | 4.3 |
| Phase I Dose Escalation - Dose Level 2 | 4.7 | 7.0 | 8.5 | 9.4 | 11.3 | 12.0 | 12.1 | 7.9 |
| Phase I Dose Escalation - Dose Level 3 | 3.5 | 6.4 | 7.5 | 8.3 | 9.5 | 8.9 | 7.8 | 5.8 |
"Responses were assessed according to the International Working Group Criteria for AML. All patients who received at least one dose of AMD3100 were considered evaluable for response.~Response rate was the rate of complete remission plus complete remission with incomplete blood count recovery (CR + CRi)." (NCT00512252)
Timeframe: 42 days
| Intervention | percentage of participants (Number) | |
|---|---|---|
| CR + CRi | CR only | |
| >= Second Relapse/Salvage | 25 | 25 |
| First Relapse, First Salvage | 56 | 47 |
| Primary Refractory | 20 | 20 |
| Total | 46 | 39 |
Treatment related mortality (deaths occurring during treatment) (NCT00512252)
Timeframe: 42 days
| Intervention | participants (Number) | |
|---|---|---|
| Sepsis | Adverse transfusion reaction w/febrile neutropenia | |
| Phase II Dose Treatment | 2 | 1 |
Treatment failures includes those patients for whom treatment has failed to achieve a CR or a CRi. (NCT00512252)
Timeframe: 42 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Persistent leukemia | Death during aplasia | Unknown | |
| >= Second Relapse/Salvage | 3 | 0 | 0 |
| First Relapse, First Salvage | 12 | 1 | 1 |
| Primary Refractory | 6 | 2 | 0 |
| Total | 21 | 3 | 1 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
6 reviews available for mitoxantrone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical | 2012 |
[Adjuvant and additive therapy for cancer of the pancreas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as T | 2003 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
Chemotherapy for high-risk localized prostate cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Mitoxantrone; Neoadjuvant Th | 2006 |
Hormone-refractory (D3) prostate cancer: refining the concept.
Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Hu | 1995 |
[Primary MALT-type lymphoma of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1998 |
53 trials available for mitoxantrone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, A | 2023 |
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hyd | 2019 |
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resis | 2019 |
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra | 2015 |
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2015 |
A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; | 2016 |
Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Kaplan | 2009 |
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin | 2012 |
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin | 2012 |
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin | 2012 |
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin | 2012 |
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Doxorubicin; Female; Humans; Male; Middle | 2003 |
The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2003 |
Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra | 2003 |
[Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Tran | 2003 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adj | 2004 |
Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Chemotherapy, | 2005 |
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2005 |
A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2003 |
Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Br | 2006 |
Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Disease-Free Surv | 2007 |
Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 2007 |
Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Me | 2007 |
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Fema | 2007 |
Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Cells, Cultured; Clinical Trials | 1983 |
Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Transitional Ce | 1995 |
Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Hu | 1995 |
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Cyc | 1995 |
[Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1995 |
Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1995 |
Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer.
Topics: Adult; Aged; Ascites; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administrati | 1994 |
Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmu | 1996 |
Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, A | 1997 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Co | 1997 |
Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Dexamethasone; Female; Huma | 1999 |
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disea | 1999 |
5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2001 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Fr | 2001 |
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter | 2001 |
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Magnetic Re | 2001 |
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diseas | 2002 |
Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2002 |
ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Daca | 2002 |
Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Injec | 1991 |
Chemotherapy for invasive thymoma. A 13-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1991 |
Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Leiomyosarcoma; Middle Aged; Mitoxantrone; Multicenter | 1990 |
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-H
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Child | 1990 |
[Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clini | 1986 |
90 other studies available for mitoxantrone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bortezomib; Child; Child, | 2020 |
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cyt | 2021 |
Multimodality therapy for thymoma patients with pleural dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; | 2019 |
Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; CD8-Positive T | 2019 |
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau | 2013 |
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2015 |
High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female | 2016 |
Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.
Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Humans; Idarubicin; In Situ Hybr | 2016 |
Nonfunctioning Adrenocortical Carcinoma in Pediatric Acute Lymphoblastic Leukemia: A Case Report of a Rare Multiple Primaries Combination.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2017 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
Race and intensity of post-remission therapy in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black Pe | 2011 |
FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Femal | 2011 |
Salvaging AML with CLAG: novel option, or more of the same?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Granulocyte Colon | 2011 |
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabi | 2011 |
Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dexame | 2012 |
Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2012 |
A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female | 2002 |
Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Mitox | 2003 |
Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2003 |
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2005 |
Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Heart Neoplasms; Human | 2005 |
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; | 2005 |
Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Sur | 2005 |
[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Dexamethasone; Do | 2005 |
Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2007 |
[A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2007 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexa | 2007 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Mi | 1984 |
Mitoxantrone in patients with acute leukemia in relapse.
Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Child; Drug Administration | 1983 |
Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 1996 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemot | 1995 |
Previously treated, locally recurrent breast cancer: treatment with superselective intraarterial chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Mitoxantrone; | 1995 |
[Pleomorphic T-cell lymphoma. The diagnostic problems, therapeutic possibilities and infection-induced complications].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Cyclophosphamide; Cy | 1993 |
Treatment of locally recurrent male breast cancer by regional chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Chemotherapy, Cancer, | 1995 |
TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 1994 |
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide | 1994 |
Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; Humans; | 1994 |
Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study.
Topics: Adult; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Female; Foll | 1994 |
Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chromatography, Hig | 1994 |
Intravesical mitoxantrone in superficial bladder tumours (Ta-T1).
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cystitis; Humans; Mitoxantrone; Neoplasm | 1993 |
Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Infusions, Parenter | 1993 |
[Superselective intra-arterial chemotherapy in breast cancer].
Topics: Adult; Aged; Angiography; Breast Neoplasms; Female; Humans; Infusions, Intra-Arterial; Mammary Arter | 1993 |
Intravesical mitozantrone in recurrent superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Humans; Mitoxantrone; Neoplasm Recurrence, Loca | 1995 |
[Percutaneous drainage of refractory necrotizing tumors: experience in 9 patients].
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Cystadenocarcinoma; Drainage; Female; His | 1995 |
Local hyperthermic treatment does not enhance mitoxantrone effectiveness for responses of a rat solid tumour regrowing after irradiation.
Topics: Animals; Antineoplastic Agents; Cell Division; Combined Modality Therapy; Female; Hyperthermia, Indu | 1996 |
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antigens, CD7; Antineopla | 1996 |
Late relapse after autologous BMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophospham | 1996 |
Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.
Topics: Adult; Antineoplastic Agents; Catheters, Indwelling; Chemotherapy, Cancer, Regional Perfusion; Elect | 1996 |
A possible correlation between growth-factor sensitivity and response to mitoxantrone treatment in a murine myeloid leukaemia (SA7HD) cell line.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Count; Cell Division; Culture Media, Conditioned; | 1997 |
[Mitoxantrone-induced acute left heart failure after intrapleural administration].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Dose-R | 1997 |
[Preoperative irradiation and interstitial radiotherapy-hyperthermia boost in breast tumors > or = 3 cm. The Düsseldorf experience].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A | 1997 |
[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 1998 |
[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami | 1997 |
High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; | 1998 |
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Com | 2000 |
[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Administratio | 2000 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Recurrent gastrointestinal stromal sarcomas.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Humans; Injection | 2000 |
Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Axilla; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Combin | 2000 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combi | 2001 |
Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogen | 2001 |
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Ca | 2002 |
Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cytar | 1992 |
Leiomyosarcoma of the great saphenous vein.
Topics: Combined Modality Therapy; Female; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Mitoxantrone | 1992 |
High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adult; Bone Marrow Transplantation; Etoposide; Female; Heart Diseases; Hodgkin Disease; Humans; Male | 1992 |
Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; | 1992 |
[Intravenous mitoxantrone use and simultaneous radiotherapy as a palliative treatment in recurrent head and neck tumors].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Modality Therapy; Female; Head | 1991 |
[Intra-arterial chemotherapy in locally advanced breast carcinomas].
Topics: Adult; Angiography, Digital Subtraction; Breast Neoplasms; Female; Humans; Infusions, Intra-Arterial | 1991 |
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubic | 1991 |
Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; | 1991 |
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea | 1990 |
[Chemotherapy of highly malignant thyroid tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Small Cell; Cisplatin; C | 1990 |
Phase I and pharmacology study of intravesical mitoxantrone for recurrent superficial bladder tumors.
Topics: Administration, Intravesical; Adult; Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Mitox | 1990 |
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl | 1990 |
Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Etoposide; Female; Humans; Infusions, Intravenous; Leuk | 1990 |
Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Female; Humans; Le | 1990 |
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor | 1989 |
Treatment with locally applied mitoxantrone.
Topics: Catheters, Indwelling; Female; Humans; Infusions, Parenteral; Male; Mediastinal Neoplasms; Mitoxantr | 1989 |
[Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance | 1989 |
[Tolerance of intraoperative, intraperitoneal chemotherapy in advanced gynecologic malignancies].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female | 1988 |
Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma.
Topics: Adenocarcinoma; Aged; Drug Evaluation; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Recurrenc | 1987 |
[Mitoxantrone in metastatic cylindromas. Apropos of a case].
Topics: Adult; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitoxantrone; Neoplasm Recurrence, Loca | 1987 |
Phase II study of high-dose mitoxantrone in the treatment of recurrent squamous cell carcinoma of the head and neck.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Drug Evaluation; Drug Tolerance; Female; Head and | 1987 |
Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group Study.
Topics: Adult; Aged; Anthraquinones; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Middle Aged; | 1986 |
Mitoxantrone in advanced cervical carcinoma: a phase II study in patients not previously treated with chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Hematologic Diseases; Humans; Middle | 1986 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |
[Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1985 |